Evidence map›Paper›PMID 36711154›Full record

ArticleFrontiers in neuroscience2022

New insights into the regulation of

Pierre Conan, Alice Léon, Noéline Caroff, Claire Rollet, Loubna Chaïr, Jennifer Martin, Frédéric Bihel, Olivier Mignen, Cécile Voisset, Gaëlle Friocourt

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Role of cystathionine-β-synthase and hydrogen sulfide in down syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Pierre ConanINSERM, Université de Brest, EFS, UMR 1078, GGB, Brest, France.
Alice LéonINSERM, Université de Brest, EFS, UMR 1078, GGB, Brest, France.
Noéline CaroffINSERM, Université de Brest, EFS, UMR 1078, GGB, Brest, France.
Claire RolletINSERM, Université de Brest, EFS, UMR 1078, GGB, Brest, France.
Loubna ChaïrINSERM, Université de Brest, EFS, UMR 1078, GGB, Brest, France.
Jennifer MartinINSERM, Université de Brest, EFS, UMR 1078, GGB, Brest, France.
Frédéric BihelLaboratoire d'Innovation Thérapeutique, UMR 7200, IMS MEDALIS, Faculty of Pharmacy, CNRS, Université de Strasbourg, Illkirch, France.
Olivier MignenU1227, Lymphocytes B, Autoimmunité et Immunothérapies, INSERM, Université de Brest, Brest, France.
Cécile VoissetINSERM, Université de Brest, EFS, UMR 1078, GGB, Brest, France.
Gaëlle FriocourtINSERM, Université de Brest, EFS, UMR 1078, GGB, Brest, France.
Inserm · FRUniversité de Bretagne Occidentale · FRGénétique, Génomique Fonctionnelle et Biotechnologies · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Down syndrome (DS), the most frequent chromosomic aberration, results from the presence of an extra copy of chromosome 21. The identification of genes which overexpression contributes to intellectual disability (ID) in DS is important to understand the pathophysiological mechanisms involved and develop new pharmacological therapies. In particular, gene dosage of

Indexed as

AktCBSDYRK1AGSK3βNF-κBpharmacological inhibitor

Identifiers

PMID36711154
PMCPMC9879293
OpenAlexW4315479855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.